This article is more than 5 years old. Information may no longer be current.

Expanded 2-year follow-up supports ranibizumab for DME

Ophthalmology. 2011;118(4):609-614.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Consistent best corrected visual acuity and safety results suggest that ranibizumab should be considered for the treatment of diabetic macular edema, a study found.

The Diabetic Retinopathy Clinical Research Network (DRCR.net) multicenter, randomized clinical trial assessed 854 eyes treated with either sham injection with prompt focal/grid laser, intravitreal 0.5 mg Lucentis (ranibizumab, Genetech) with prompt or deferred laser, or 4 mg triamcinolone with prompt laser.

At 24 months, the ranibizumab plus prompt laser group and the ranibizumab plus deferred laser group achieved mean visual acuity improvements of 3.7 and 5.8 letters, respectively, greater than improvements in the sham plus prompt laser group. Conversely, mean visual acuity for the triamcinolone group, compared with the sham plus laser group, was 1.5 letters lower.

On average, patients in the ranibizumab plus prompt or deferred laser groups underwent two to three injections, and no systemic events that could be attributed to treatment were observed.

However, three eyes in the ranibizumab groups experienced injection-related endophthalmitis, while cataract surgery and elevated IOP were more prevalent in the triamcinolone group.